Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ARQT - Arcutis Biotherapeutics, Inc.
Market Cap 629.58M P/E - EPS this Y 59.00% Ern Qtrly Grth -
Income -198.76M Forward P/E -2.76 EPS next Y 25.80% 50D Avg Chg 8.00%
Sales 132.06M PEG -0.60 EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 4.50 EPS next 5Y 9.80% 52W High Chg -63.00%
Recommedations 1.90 Quick Ratio 7.90 Shares Outstanding 116.89M 52W Low Chg 41.00%
Insider Own 2.19% ROA -29.36% Shares Float 85.87M Beta 1.18
Inst Own 110.43% ROE -148.92% Shares Shorted/Prior 24.86M/23.80M Price 10.25
Gross Margin 92.32% Profit Margin -150.51% Avg. Volume 1,262,433 Target Price 18.57
Oper. Margin -162.28% Earnings Date Nov 1 Volume 568,776 Change -3.03%
Healthcare | Biotechnology | United States
About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc. News
10/12/24 Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments
10/09/24 Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)
10/04/24 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/03/24 Exploring High Growth Tech Stocks In The US October 2024
09/25/24 New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
09/24/24 FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
09/19/24 Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
09/06/24 Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
09/05/24 Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
09/04/24 Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now
08/28/24 Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
08/27/24 Exploring Three High Growth Tech Stocks In The United States
08/22/24 Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
08/15/24 Q2 2024 Arcutis Biotherapeutics Inc Earnings Call
08:00 PM CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
04:10 PM Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
03:00 PM Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
08/13/24 Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long
08/07/24 Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
08/01/24 Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
ARQT Chatroom

User Image NobVega Posted - 4 hours ago

$ARQT 31% short, 27M shares. One whale could wipe them out. Come on down Baker Brothers. We miss $10.

User Image Finsh1st Posted - 5 hours ago

$ARQT it's mostly 12.50 calls expire Friday. Bleh...

User Image Rhody27 Posted - 7 hours ago

$ARQT this will finish close to green as usual.

User Image Franciscomaligno Posted - 7 hours ago

$ARQT MM's are REALLY getting boring !!! Quiet before the thunder ???

User Image Carl83 Posted - 8 hours ago

$ARQT Added a few hundred more

User Image NobVega Posted - 3 days ago

$ARQT What the hell was today about. Got scared but held my 4,000 shares.

User Image NobVega Posted - 3 days ago

$ARQT Are we going to get scripts from our partner in Japan in November?

User Image Rhody27 Posted - 3 days ago

$ARQT don't you ever take a day off shorts?

User Image Finsh1st Posted - 3 days ago

$ARQT Biotech is murdering it today... yet the shorts aren't batting and eye... bleh...

User Image leonbnu Posted - 3 days ago

$ARQT drop because of the script number?

User Image zawojak Posted - 3 days ago

$ARQT shorts attack, fundamentals haven't changed

User Image Finsh1st Posted - 3 days ago

$ARQT

User Image NobVega Posted - 3 days ago

$ARQT Can't find any news to warrant this sell off.

User Image zawojak Posted - 3 days ago

$ARQT cheapies

User Image liadanielle Posted - 4 days ago

$ARQT I have a 30% rule with certain stocks. Arqt is a long play although I do take profit at 30% still keeping shares on hold

User Image zawojak Posted - 4 days ago

$ARQT dead money until Nov earnings

User Image Finsh1st Posted - 5 days ago

$ARQT I do keep adding shares early. My adding area I had set at 9.50 increasing quantity until 8$ just I always get too involved and alter my plan, or just let that instant gratification need take hold. Honestly, if I told someone a good investment, they would make decent $... all the defense stocks I panic sold 4 months ago... that kind of stuff. I just need patience and faith in my investments when i buy at a decent price, or not. I'm posting this, so next time, maybe just maybe, I'll stick to my plan and make some actual $. K... bullish long-term

User Image Finsh1st Posted - 5 days ago

$ARQT Calls expire next Friday. My guess shorts let off Friday, MMs sell 10$ calls early week, then smash it back down hard. Maybe run her like 10.60s max...guess...

User Image BugHunti Posted - 5 days ago

$ARQT under 8$

User Image liadanielle Posted - 6 days ago

$ARQT Fear not. Keep adding. Great company. Irons in the fire. 16$. 6 months After election

User Image mcube1820 Posted - 6 days ago

$ARQT Pump and dump again.

User Image RoyMunson69 Posted - 6 days ago

$ARQT This just isn’t going anywhere its cooked

User Image NobVega Posted - 6 days ago

$ARQT It appears 24.8M short getting squeezed by some institutional whales. Bout time we see a rise to $11 into earnings.

User Image Finsh1st Posted - 6 days ago

$ARQT meh

User Image NobVega Posted - 1 week ago

$ARQT Does the CEO and BOD buy at these levels? I know they sold 18M shares at $9.50 to institutional investors to grow sales, but when is the payoff? November earnings seems far off.

User Image Carl83 Posted - 1 week ago

$ARQT buy the deeeeep!

User Image Finsh1st Posted - 1 week ago

$ARQT

User Image zawojak Posted - 1 week ago

$ARQT it's time to go to $12 🥹

User Image Finsh1st Posted - 1 week ago

$ARQT 11 new employees. Work to be done! https://finance.yahoo.com/news/arcutis-biotherapeutics-reports-inducement-grants-200000274.html

User Image Finsh1st Posted - 1 week ago

$ARQT Plz Arcutis release some huge contract or merger over the weekend. Burn these shorts, oh lord. 🙏 smite shorti

Analyst Ratings
Jefferies Buy Aug 28, 24
Needham Buy Aug 15, 24
Needham Buy Jul 30, 24
Needham Buy Jul 10, 24
Needham Buy May 15, 24
Mizuho Buy May 15, 24
Needham Buy Apr 12, 24
Goldman Sachs Neutral Feb 28, 24
Mizuho Buy Feb 28, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Burnett Patrick See Remarks See Remarks Jan 02 Sell 3.5408 1,325 4,692 57,032 01/03/24
Watanabe Todd Franklin See Remarks See Remarks May 31 Buy 6.38 1,463 9,334 515,145 12/01/23
Watanabe Todd Franklin See Remarks See Remarks May 31 Option 1.68 59,525 100,002 513,682 12/01/23
Matsuda Masaru See Remark See Remark Nov 18 Sell 1.98 1,850 3,663 46,634 11/21/23
Burnett Patrick See Remarks See Remarks Aug 18 Sell 7.05 1,605 11,315 58,357 08/22/23
Matsuda Masaru See Remark See Remark May 27 Sell 7.8 1,830 14,274 42,146 06/02/23
Welgus Howard G. Director Director Apr 17 Sell 13.97 8,500 118,745 165,825 04/18/23
Welgus Howard G. Director Director Apr 17 Option 1.68 8,500 14,280 174,325 04/18/23
Moore Matthew Richard See Remarks See Remarks Mar 02 Sell 16.17 1,610 26,034 11,690 03/06/23
Matsuda Masaru See Remarks See Remarks Mar 02 Sell 16.17 1,434 23,188 18,101 03/06/23
Burnett Patrick See Remarks See Remarks Mar 02 Sell 16.17 1,751 28,314 39,813 03/06/23
Watanabe Todd Franklin See Remarks See Remarks Feb 28 Sell 16.17 7,815 126,369 369,092 03/02/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 16.17 1,850 29,915 38,406 03/02/23
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Feb 28 Sell 16.17 2,368 38,291 43,260 03/02/23
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Feb 28 Sell 16.17 2,005 32,421 254,644 03/02/23
Welgus Howard G. Director Director Feb 15 Sell 16.98 8,500 144,330 165,825 02/21/23
Welgus Howard G. Director Director Feb 15 Option 1.68 8,500 14,280 174,325 02/21/23
Watanabe Todd Franklin See Remarks See Remarks Feb 13 Sell 17.02 1,000 17,020 376,907 02/15/23
Welgus Howard G. Director Director Jan 17 Sell 13.72 8,500 116,620 165,825 01/18/23
Welgus Howard G. Director Director Jan 17 Option 1.68 8,500 14,280 174,325 01/18/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Sep 16 Option 1.6806 5,000 8,403 40,256 09/20/22
Watanabe Todd Franklin President and CEO President and CEO Sep 07 Sell 21.51 1,000 21,510 381,907 09/09/22
Welgus Howard G. Director Director Aug 15 Sell 24.7981 6,000 148,789 174,208 08/17/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Option 1.68 2,500 4,200 654,371 08/09/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Sell 24.74 2,500 61,850 651,871 08/09/22
Frazier Life Sciences VIII, L.... 10% Owner 10% Owner Aug 05 Buy 20.00 250,000 5,000,000 8,684,232 08/09/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 23 Option 6.52 15,331 99,958 46,444 08/04/22
Welgus Howard G. Director Director Jul 18 Sell 24.3956 6,000 146,374 180,208 07/18/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Jul 08 Sell 25.4144 2,197 55,835 256,649 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Option 1.68 7,087 11,906 658,958 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Sell 25.28 13,500 341,280 651,871 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 06 Sell 22.07 1,000 22,070 658,284 07/07/22
Watanabe Todd Franklin President and CEO President and CEO May 05 Sell 21.76 1,000 21,760 658,667 05/05/22
Welgus Howard G. Director Director May 02 Option 1.13 2,500 2,825 184,396 05/03/22
Welgus Howard G. Director Director May 02 Sell 20.44 2,500 51,100 181,896 05/03/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Apr 21 Sell 20.4243 2,197 44,872 257,229 04/21/22
ORBIMED ADVISORS LLC 10% Owner 10% Owner Apr 06 Sell 20.69 878,200 18,169,958 451,086 04/08/22
Watanabe Todd Franklin President and CEO President and CEO Apr 05 Sell 21.43 1,000 21,430 659,667 04/05/22
Welgus Howard G. Director Director Apr 01 Option 0.58 7,500 4,350 189,396 04/01/22
Welgus Howard G. Director Director Apr 01 Sell 20.02 7,500 150,150 181,896 04/01/22
Watanabe Todd Franklin President and CEO President and CEO Mar 09 Sell 17.00 300 5,100 660,667 03/11/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Option 1.68 700 1,176 661,667 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Sell 16.8 3,259 54,751 660,967 03/07/22
Burnett Patrick See Remarks See Remarks Mar 03 Sell 16.65 1,011 16,833 43,039 03/07/22
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Mar 03 Sell 16.65 1,023 17,033 44,011 03/07/22
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Mar 03 Sell 16.65 303 5,045 35,256 03/07/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 03 Sell 16.65 1,023 17,033 31,113 03/07/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Mar 03 Sell 16.65 856 14,252 259,426 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Option 1.68 1,000 1,680 595,779 02/11/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Sell 17 1,000 17,000 594,779 02/11/22